FDA Grants Priority Review for Rucaparib
December 28, 2017 8:08 pmThe US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more